PRSS-56 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Human PRSS-56 (UniProt P0CW18) recombinant protein expressed in HEK293 cells. 603-aa serine protease required for ocular development; suited for activity assays, inhibitor screening, and antibody validation.
Expression system
HEK293
Cat. #
REC-PRSS56

In stock

SKU
REC-PRSS56
$498.00

Target Overview

PRSS-56 (UniProt P0CW18; gene PRSS56) is a 603-amino-acid serine protease classified under EC 3.4.21.- and required during eye development. This recombinant form is produced in HEK293 mammalian cells, providing a eukaryotic expression environment that supports the post-translational processing and folding characteristic of the native human protein — attributes particularly relevant for serine proteases whose activity depends on correct zymogen maturation and disulfide architecture. The full-length sequence spans 603 residues. Because HEK293-derived material undergoes mammalian glycosylation and signal-peptide processing, this recombinant is well suited to enzymatic characterisation studies where conformational fidelity matters. Researchers routinely employ recombinant PRSS-56 in fluorogenic substrate cleavage assays to define substrate preference and kinetic parameters (Km, kcat), and in small-molecule inhibitor screens to determine IC50 values against serine protease inhibitor scaffolds. A second primary use is antibody validation. Recombinant PRSS-56 serves as a defined positive-control antigen in Western blot titration experiments and dot-blot assays, enabling researchers to confirm antibody specificity before committing to tissue or cell-lysate experiments. Researchers using this recombinant for antibody validation work can pair it directly with the matched Triple Point Biologics anti-PRSS56 antibody (SKU: RP-PRSS56), which has been validated for Western blot against human targets. The protein is also appropriate for surface plasmon resonance (SPR) or bio-layer interferometry (BLI) binding studies aimed at identifying protein-protein interaction partners relevant to its developmental signalling context, and for generating standard curves in quantitative ELISA formats where a sequence-verified, species-matched antigen is required.

Background

PRSS56 encodes a serine protease (EC 3.4.21.-; UniProt P0CW18) with an established, specific role in ocular development. Loss-of-function variants in PRSS56 are the principal monogenic cause of autosomal-recessive nanophthalmos and posterior microphthalmia — conditions characterised by a pathologically short axial length and consequently high hyperopia. The mechanistic basis relates to the protease's activity during the period of postnatal eye growth, though the precise substrate cascade downstream of PRSS56 in the developing retina and sclera remains an active area of investigation, making recombinant protein reagents central to ongoing substrate-identification and pathway-mapping studies. The genetic association is now supported by multi-ethnic cohort data. Whole-exome sequencing of Chinese patients with microphthalmia identified novel PRSS56 variants segregating with disease (Luo et al., 2026, BMC Med Genomics, PMID 42015194), extending the variant spectrum beyond the founder mutations originally described in consanguineous European and Middle Eastern families. Complementary longitudinal work in a Saudi cohort has characterised the visual function trajectory in PRSS56-related posterior microphthalmia over time (Almhmoudi et al., 2026, J AAPOS, PMID 42184889), providing clinical phenotype data that research groups use to design functional experiments correlating variant severity with residual protease activity — experiments that depend directly on recombinant PRSS-56 preparations for in-vitro enzymatic benchmarking. From a structural biology perspective, PRSS56 belongs to the S1 family of trypsin-like serine proteases. Researchers investigating whether specific missense variants abolish catalytic activity (through disruption of the canonical Ser-His-Asp catalytic triad) or instead impair secretion and folding use recombinant wild-type PRSS-56 as the reference standard against which variant proteins are compared in parallel activity assays. This application is particularly important for interpreting variants of uncertain significance (VUS) identified by clinical sequencing programmes. Beyond ocular biology, PRSS56 expression data from proteomics and transcriptomics pipelines has placed it in broader signalling contexts, and the protein's classification as an extracellular or secreted serine protease suggests potential roles in pericellular matrix remodelling. Recombinant PRSS-56 is used in substrate-mapping experiments — including positional scanning synthetic combinatorial libraries and mass spectrometry-based degradomics — aimed at defining the full substrate repertoire and identifying endogenous inhibitors or co-factors that modulate its activity during development.

Applications

  • Fluorogenic peptide substrate cleavage assay to determine Km and kcat for candidate serine protease substrates
  • Small-molecule inhibitor IC50 determination using continuous fluorescence read-out formats
  • Western blot positive-control antigen for anti-PRSS56 antibody validation (pairs with Triple Point Biologics RP-PRSS56)
  • ELISA standard curve generation using sequence-verified recombinant antigen
  • Surface plasmon resonance (SPR) or bio-layer interferometry (BLI) binding studies to identify protein-protein interaction partners
  • Variant functional benchmarking — comparison of wild-type vs. missense-variant PRSS-56 catalytic activity in parallel in-vitro assays
  • Mass spectrometry-based substrate identification (degradomics) to map the PRSS-56 cleavage specificity profile

References

  1. Almhmoudi F et al. Posterior microphthalmia related to PRSS56 variants in a Saudi cohort: a longitudinal study of visual function. J AAPOS. 2026. doi:10.1016/j.jaapos.2026.104865. PMID: 42184889.
  2. Luo J et al. Whole-exome sequencing identifies PRSS56 variants in Chinese patients with microphthalmia. BMC Med Genomics. 2026. doi:10.1186/s12920-026-02376-9. PMID: 42015194.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted (most); pancreas + serum (digestive proteases)

Frequently Asked Questions

What is the expected molecular weight of recombinant PRSS-56 on SDS-PAGE and Western blot?

The PRSS-56 open reading frame encodes 603 amino acids, giving a predicted unmodified MW of ~67 kDa. Because this recombinant is produced in HEK293 cells and undergoes mammalian N-linked glycosylation, the apparent MW on SDS-PAGE typically runs at 75–85 kDa — a shift consistent with glycoprotein behaviour. On Western blot under reducing conditions, expect a diffuse band in that 75–85 kDa window. Purity is confirmed >95% by SDS-PAGE prior to release. If you are using our matched antibody RP-PRSS56 for the blot, this band serves as your positive control reference.

Is recombinant PRSS-56 supplied as a zymogen or as the mature processed form?

PRSS-56 is a serine protease that undergoes zymogen maturation; the HEK293 expression system used here supports signal-peptide cleavage and the post-translational folding required for correct disulfide architecture. The recombinant supplied by Triple Point Biologics is the processed, active-enzyme form — not the uncleaved zymogen. This is relevant if you are running substrate-cleavage or inhibitor assays where pre-activation steps would otherwise introduce variability. The active form also means you can proceed directly to kinetic characterisation without an in vitro activation protocol.

What fluorogenic substrate should I use to measure PRSS-56 serine protease activity?

PRSS-56 is classified under EC 3.4.21.- (serine endopeptidases). For initial activity screening, synthetic fluorogenic substrates with a Arg-AMC or Lys-AMC scaffold (e.g., Boc-Phe-Ser-Arg-AMC or H-Arg-AMC) are a reasonable starting point given the trypsin-like cleavage preference common to this class. Monitor release of AMC fluorescence at Ex 380 nm / Em 460 nm. Because PRSS-56's precise substrate preference is still being characterised in the literature, we recommend running a substrate panel at 100–200 µM substrate concentration against 50–200 nM enzyme to identify highest-signal hits before committing to kinetic measurements.

What assay buffer conditions work best for PRSS-56 activity assays?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — is compatible with direct use in activity assays at low dilution, provided glycerol carry-over does not exceed ~1% in the final reaction volume. For kinetic assays (Km, kcat determination), dilute enzyme into a working buffer of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.01% Tween-20 to minimise surface adsorption at low enzyme concentrations. Avoid Ca²⁺ chelators (EGTA, EDTA) unless your experimental design requires them. Maintain pH between 7.0 and 8.0; serine protease activity typically drops sharply below pH 6.5.

What starting enzyme concentration should I use for an IC50 inhibitor screen against recombinant PRSS-56?

For a well-behaved IC50 determination, enzyme concentration in the assay well should be at or below the anticipated Ki of your inhibitor scaffold — typically 10–50 nM recombinant PRSS-56 is a practical starting range. Run an activity-versus-concentration curve first (1–500 nM) to identify a linear signal window. Substrate should be held below Km (empirically determined) to satisfy the Morrison tight-binding assumptions if you expect sub-nanomolar inhibitors. Pre-incubate enzyme with inhibitor for 30 min at room temperature before substrate addition to allow equilibrium binding. Stock concentration of REC-PRSS56 should be verified by A280 or BCA before the screen.

Can I use recombinant PRSS-56 (REC-PRSS56) as a positive control for Western blot with the matched antibody RP-PRSS56?

Yes — this is one of the primary use cases for REC-PRSS56 alongside RP-PRSS56. The rabbit polyclonal antibody RP-PRSS56 was validated against this recombinant in-house, so the two reagents are guaranteed compatible for Western blot positive-control applications. Load 50–100 ng of REC-PRSS56 per lane under reducing conditions; you should see a clean band at 75–85 kDa with RP-PRSS56 at its recommended primary antibody dilution. This also makes REC-PRSS56 a reliable standard for antibody lot-to-lot consistency checks and for validating antibody performance in new cell or tissue lysate backgrounds.

How much recombinant PRSS-56 should I load for a Western blot positive control lane?

50–100 ng per lane is sufficient for a strong, clean signal with RP-PRSS56 on standard PVDF or nitrocellulose membranes. If you are optimising antibody dilution simultaneously, running a titration of 10, 25, 50, and 100 ng across adjacent lanes gives a useful signal-linearity check. Resolve on a 10% or gradient (8–12%) SDS-PAGE gel to best resolve the 75–85 kDa glycosylated band. At >200 ng the band can appear diffuse due to glycan heterogeneity, which is normal for HEK293-expressed glycoproteins and does not indicate protein degradation.

How should I store and handle recombinant PRSS-56 to preserve enzymatic activity long-term?

REC-PRSS56 is shipped in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and arrives ready to use — no reconstitution required. Store at -20°C in the single-use aliquots provided; repeated freeze-thaw cycles progressively reduce activity and should be avoided. For working stocks used within a week, storage at 4°C is acceptable, but activity loss beyond 5–7 days at 4°C has been observed for serine proteases of this class. Add BSA (0.05–0.1 mg/mL) to diluted working solutions to reduce adsorptive losses at low enzyme concentrations (<10 nM). Do not heat above 37°C during assay setup.

Validation imagery coming soon

Western blot validation figures for REC-PRSS56 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →